Azhar Ali Chaudhry

Dr. Azhar Ali Chaudhry

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2026 in Pakistan Heart Journal
Verified
Journal Article
Open access
PDF file
MHMohammad Hafizullah
Mohammad Hafizullah
ZSZainab Samad
Zainab Samad
TJTazeen Jafar
Tazeen Jafar
KKKhawar Abbas Kazmi
Khawar Abbas Kazmi
BHBashir Hanif
Bashir Hanif
ICIrfan Elahi Chandna
Irfan Elahi Chandna
Background and Rationale Pakistan’s trajectory is alarming. Between 1990 and 2019, annual cardiovascular disease (CVD) deaths nearly doubled—from 172,526 to 341,108. Age-standardized mortality rates (ASMR) increased rather than declined, in contrast to global trends. Coronary artery disease remains the dominant contributor to disability-adjusted life years (DALYs), affecting both men and women [1]. Recent post-COVID analyses further warn that Pakistan faces a prolonged surge in CVD unless decisive prevention strategies are adopted [2,3]. The most recent Global Burden of Cardiovascular Disease (GBD) report underscores a critical truth: “The GBD is sometimes viewed as a mirror—a detailed reflection of where we are. But its real power is as a compass, pointing us toward where we must act” [1]. The compass now points clearly toward three global priorities: Hypertension control—the single intervention with the greatest population impact. Urgent action on obesity and diabetes—a rapidly rising tide. Strengthening health systems—to deliver prevention and care reliably, equitably, and at scale [4]. Cardiovascular disease is now Pakistan’s leading cause of death, a major driver of healthcare expenditure, productivity loss, and premature mortality. A coherent national prevention policy must therefore be population-wide, equitable, affordable, and grounded in local realities [5]. References Jabbar ABA, Mansoor T, Javed MA, Minhas AMK. Burden of cardiovascular diseases in a developing country—insight from Global Burden of Disease Study 2019. J Am Coll Cardiol. 2025;85(12 Suppl):2693. DOI: 10.1016/S0735-1097(25)03177-8 Hafizullah M. Preventive cardiology—the only way out! Pak Heart J. 2012;45(1):1-4. Samad Z, Hanif B. Cardiovascular diseases in Pakistan: imagining a postpandemic, postconflict future. Circulation. 2023;147(17):1261-3. DOI: 10.1161/CIRCULATIONAHA.122.059122 Krumholz HM. The global burden of cardiovascular disease: not just a mirror, but a compass. J Am Coll Cardiol. 2025;86(22):2103-5. DOI: 10.1016/j.jacc.2025.09.1584 Nishtar S, Faruqui AM, Mattu MA, Mohamud KB, Ahmed A. The National Action Plan for the Prevention and Control of Non-communicable Diseases and Health Promotion in Pakistan—cardiovascular diseases. J Pak Med Assoc. 2004;54(12 Suppl 3):S14-25.

29 April 2026 in Cardiogenetics
Verified
Journal Article
Open access
PDF file
ICIftikhar Ch
Iftikhar Ch
ACAzhar Ali Chaudhry
Azhar Ali Chaudhry
FJFazal Jalil
Fazal Jalil
YAYasir Ali
Yasir Ali
WIWaseem Iqbal
Waseem Iqbal
KNKhurram Nasir
Khurram Nasir
Background/Objectives: Coronary artery disease (CAD) remains the leading cause of mortality worldwide, with South Asia bearing a disproportionately high and rising burden, particularly at younger ages. The present study aimed to investigate genetic variants associated with premature coronary artery disease (PCAD) using whole-genome sequencing (WGS). Methods: WGS was conducted on 12 people (five PCAD cases, seven matched controls) to assess feasibility and methodology for future large-scale research. High-quality genomic DNA was sequenced at a minimum read depth of 10× with a quality threshold of Q30. Variant calling with stringent quality control identified single-nucleotide polymorphisms (SNPs), followed by annotation against gnomAD for allele frequencies and ClinVar for pathogenicity. Protein-coding variants were filtered, and candidate genes were prioritized for comparative analysis between cases and controls. Results: An average of over 8.8 million SNPs per individual was identified, with comparable overall variant distributions between cases and controls. Initial analyses revealed 120 SNPs exclusively present in PCAD cases. All protein-coding variants were rare (allele frequency < 0.0001), and none were previously classified as pathogenic in ClinVar. After filtration, 87 candidate genes were prioritized. Enriched or unique variants in PCAD cases are mapped to genes involved in lipid metabolism, endothelial dysfunction, inflammatory signaling, immune regulation, thrombosis, vascular remodeling, and metabolic processes. Additional variants were identified in genes related to smooth muscle proliferation, oxidative stress, and other biological pathways. Conclusions: This WGS pilot study provides an initial overview of the genomic landscape of PCAD in a South Asian cohort, highlighting rare variants across multiple biological pathways implicated in atherosclerosis that need validation in a large-scale study.

Verified
Journal Article
Open access
PDF file
ICIftikhar Ch
Iftikhar Ch
ZHZahid Hasan
Zahid Hasan
ZPZongkai Peng
Zongkai Peng
KIKamrul Islam
Kamrul Islam
ASAmit Singh
Amit Singh
NANagib Ahsan
Nagib Ahsan
Premature coronary artery disease (PCAD) is a growing public health concern, especially in South Asia, where traditional risk factors fail to fully explain the increasing incidence of early-onset myocardial infarction. To explore its molecular underpinnings, we conducted a pilot study analyzing plasma proteins and lipids to identify potential biomarkers and dysregulated pathways associated with PCAD. Label-free quantitative proteomics revealed distinct molecular signatures separating PCAD patients from age- and sex-matched healthy controls. Key alterations included upregulation of GALE, immunoglobulin genes, and KIF20B, suggesting enhanced inflammatory responses and proliferative activity associated with post-myocardial infarction cellular repair. Similarly, down regulations of various proteins linked to multiple functions, such as myocardial infarction, hemoglobinopathy, complement and coagulation cascade, and fatty acid and lipoprotein transport in hepatocytes, were observed. Untargeted lipidomics further revealed significant elevations in several phosphatidylcholine species (PC 42:5, PC 40:3, and PC 42:7), highlighting disruption of highly unsaturated phospholipid metabolism. Overall, these findings indicate that PCAD is a multifactorial disorder involving metabolic, immune, and vascular dysfunction beyond conventional lipid abnormalities, underscoring the need for larger cohort studies to validate these biomarkers and uncover novel therapeutic targets.